Ralf Schmid
Independent Expert Independent Expert
Ralf Schmid is an independent expert specializing in the preclinical development of AAV gene therapies, RNAi/ASO platforms, and gene editing technologies. He provides strategic guidance on therapeutic innovation through deep-dive analyses of competitive landscapes and unmet clinical needs. His prior leadership roles include Associate Director at Novartis Neuroscience Genetic Medicines and Research Director at the University of Pennsylvania’s Gene Therapy Program.
Seminars
Tuesday 24th March 2026
Panel Discussion: Scaling Clinical Operations to Support Gene Therapies for Larger Populations
9:00 am
- Highlighting the limitations of current small-batch methods in meeting the needs of larger patient populations
- Understanding the unique manufacturing, financial, and regulatory challenges associated with working on common disease indications
- Anticipating the scientific and operational shifts needed to make gene therapy viable for high-prevalence conditions
Tuesday 24th March 2026
Evaluating the Right Modalities to Deliver Gene Therapy at Scale in Common Diseases
2:15 pm
- Comparing gene therapy to small molecules and biologics in terms of tractability and therapeutic reach
- Investigating whether advanced modalities like AAV, mRNA, or LNPs can meet the demands of high-prevalence diseases
- Delving into use cases to understand where gene therapy may offer unique value or face limitations
